Oncology nurse April Fowler shares her personal stage 4 cancer journey, reflecting on clinical empathy, patient advocacy, and oncology endurance.
News|Articles|September 10, 2026
FDA Approves Camizestrant: Key Nursing Roles in New Breast Cancer Paradigm
Author(s)Alex Biese
Fact checked by: By ONN Staff
Oncology nursing teams must navigate the clinical logistics and patient education for the newly approved, ctDNA-guided agent camizestrant.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) granted accelerated approval to the oral selective estrogen receptor degrader (SERD) camizestrant (Etcamah, AstraZeneca) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib, or ribociclib).
Related to this article
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Five-week hypofractionated radiation after prostatectomy showed similar 5-year cancer control and quality of life but more grade 3 urinary toxicity.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
Advertisement
Advertisement